Cancer Therapeutics Analysed
Research and Markets announces the addition of this new report entitled "Analytical Tool: Frontlines in Cancer Therapeutics I" to its offerings.
Cancer Category Archive
Cancer Cured. The Next Generation in Healthcare.
Exclusive members only! Each center is boldly decorated. More nightclub atmosphere than medical center. All of the sizzle and excitement of a fine casino. Be greeted and treated more as a guest than as a patient. All day "whole body" physicals are available.
PERSONALIZED CANCER VACCINE STUDY
PERSONALIZED CANCER VACCINES MAY HELP CANCER PATIENTS FIGHT DISEASE Our Lady of Mercy Cancer Center Enrolling Patients In Lymphoma Vaccine Study
World Arm Wrestling Champ, Jason Vale, in David and Goliath Battle with the FDA
Jason Vale, 35 yr old who was terminal from cancer, went on to become the Arm Wrestling World Champion, is facing another difficult opponent -- the Federal Drug Administration. Jason turned to alternative healing when he came down with cancer for the third time -- and successfully conquered cancer by prayer and eating apricot seeds, otherwise known as Laetrile. The seeds of these fruits contain Vitamin B17 (Laetrile) which has been found to have an amazing success in the healing of all types of cancers as well as preventing cancer. Jason Vale has traveled the country in arm wrestling matches since his healing, and has been interviewed by various newspapers, radio stations, and tv shows such as Extra and CNN and the Wall Street Journal. The staff of Extra received such a large number of callers after Jason's interview aired, that they aired his show a second time. Jason began to supply people with apricot seeds and an information video through a company Christian Brothers and thereafter thousands called in with success stories ranging from cancer gone to tumors shrinking down. These success stories are all documented at the website www.seedoffaith.org along with the court documents. Eventually, without even one customer compaint, the FDA came in and seized apricot seeds and computers and brought Jason to criminal court for promoting this natural answer to cancer. On July 14, 2003, in the Federal Eastern District of New York courtroom of Judge John Gleeson, Jason will defend his Constitutional Rights to be able to continue to tell his story of how he defeated one of the world's most deadliest opponents - cancer. This news worthy case has been quiet for some time now, however due to the near future trial date, Jason Vale has finally agreed to tell his side of the story; this is after turning down shows such as Date Line, 20-20 and 60 minutes.
New lines of attack and advances and
Development of an adequate blood supply is one of the essential factors that dictate malignant growth and cancer development. An extensive number of companies seek to affect tumor growth by targeting angiogenesis and neovascularisation via techniques aimed at inhibiting new blood vessel growth or destroying already existing tumor vasculature. Despite early enthusiasm for angiogenesis inhibitors as safe and effective anticancer drugs, results of several completed Phase III and Phase II trials have been disappointing. New stratagies have been developed to overcome these previous mistakes.
Provectus Working to Correct Inaccurate Reports of Large Increase in Number of Free Trading Common Shares
Knoxville,TN January 1 2004--Provectus Pharmaceuticals (OTC Bulletin Board: PVCT - News) announced today that the Company is aggressively working to correct inaccurate reporting of proposed sales of shares by the Company directors. In October 2003 Dr. Craig Dees and Dr. Tim Scott, two of our directors, each proposed to sell 94,876 shares of the Company's common stock. The Forms 144 which were actually filed with the Securities and Exchange Commission (the "SEC") erroneously indicated that Drs. Dees and Scott proposed to sell significantly more shares. Drs. Dees and Scott instructed their broker to promptly amend the Forms 144 to show the correct amount of shares that were proposed to be sold. Even after these amendments were filed with the SEC, various reporting services have continued to erroneously report that Drs. Dees and Scott have proposed to sell significantly more shares. Since the original Forms 144 were filed, neither Dr. Dees nor Dr. Scott have sold any shares.
New Innovative Antibody Strategies as Cancer Therapeutics
In this report "Antibodies as Cancer Therapeutics - R&D Situation & Business Perspectives -" we analyzed more than 300 industry related R&D projects evaluating antibody based cancer therapies. There are more than 50 companies focused on developing antibody based cancer treatments. With several approved monoclonal antibodies for at least 5 cancer indications and no less than 9 companies with projects that have reached phase III trials this field has evolved into a reality for cancer patients. Our aim has been to elucidate changes and progress in how antibodies are used for trying to cure cancer as well as describe the current and future business climate.
A Gift from the Heart
Cancer Comfort, an online cancer resource center, has officially launched a fundraising campaign for "Sarah's Gift". Sarah's Gift was created with the help of 12-year old cancer patient, Sarah, who underwent a bone marrow transplant in August 2003 at Seattle Children's Hospital.
New study analyze efforts for improved treatments of melanoma
In Europe and the US there are close to 20 million people that live with cancer today, a figure that is increasing. 6.2 million people worldwide died of cancer in 2002. The American Cancer Society estimates that approximately 1.2 million new cancer cases were diagnosed in the year 2002 in the US. Overall annual costs associated with cancer currently amount to $107 billion in the United States alone. The worldwide anti-cancer market was valued at more than $15 billion in 1998 and is projected to nearly double by 2003. Approximately 30% of all collaborative deals are signed in the field of cancer.
Tim & Tom Gullikson Foundation to Mark Its 10th Year and Announces National Week of Celebration
Ten years after the grand slam standout twin doubles team-turned coaches, Tim and Tom Gullikson, announced the formation of the Tim & Tom Gullikson Foundation to help support programs for patients and families affected by brain tumors, the United States and thousands outside the country will recognize Tim & Tom Gullikson Foundation Week, May 23-29, 2005.
The Healing of Cancer, Journeys of Self-Discovery story collection assists cancer patients with emotional, spiritual aspect of the cancer healing process.
"It always seemed during the healing of these individuals, there was a missing piece, words for the soul, messages speaking to the thought, feeling, and emotions of one with cancer. It was clear the goal of healing had a bigger piece than just the medical "mechanical" process. " --Diana Hunt, PhD.
Carolina Regional Cancer Center And Burroughs & Chapin Partner To Offer The Myrtle Beach Cancer Care Retreat
Carolina Regional Cancer Center (CRCC) has joined with Burroughs & Chapin Company, Inc. to offer the Myrtle Beach Cancer Care Retreat. The retreat, which can be individualized on a patient by patient basis, includes quality comprehensive cancer care at CRCC, accommodations at the Myrtlewood Villas in Myrtle Beach, S.C., and special rates at selected golf, entertainment and dining venues.
Eye Cancer Patients Use New Radiation-blocking Glasses to See and Function During Home Therapy
New, clear-leaded safety glasses allow eye cancer patients to see during week-long sessions of radiation therapy at home, without sacrificing safety, according to a study by Paul T. Finger, MD, director of Ocular Tumor Services at The New York Eye and Ear Infirmary, that was published in the June, 2004 issue of the American Journal of Ophthalmology.
500 million dollar industry of medications to help stop smoking
Research and Markets announces the addition of this new report entitled "Blockbuster Potential in Cancer Prevention" to its offerings.
Protein kinase inhibitors are in a position to change the future treatments of cancer
Research and Markets announces the addition of this new report entitled "Late Stage Protein Kinase Inhibitors" to its offerings.
Study on The Impact of New Drugs For The Treatment of Lung Cancer
Lung cancer is the third most common malignant disease and the first leading cause of cancer death in the western world. According to American Cancer Society predictions 173,770 will be diagnosed and 160,440 people will die by lung cancer in 2004. In the year 2002, over 800,000 people worldwide died of non-small cell lung cancer (NSCLC). More people die of lung cancer than of colon, breast, and prostate cancers combined.
KCA Survivor & Patient Conference Set for July 2004
The 12th annual Kidney Cancer Association Survivor & Patient Conference will be held in Chicago July 23 through 25, 2004, at Chicago's O'Hare Hilton Hotel. Details will be posted on the KCA website (www.nkca.org), when available. Attendees will have an opportunity to meet with leading research investigators in renal cell carcinoma. Invited speakers include physicians from major medical institutions, the National Cancer Institute, and representatives from the U.S. Food & Drug Administration.
Penn State "Lift for Life" Funds Kidney Cancer Research and Education
The Penn State Football team's first annual Penn State "Lift For Life" was a huge success, raising more than $13,000 for the Kidney Cancer Association in 2003. KCA board chair Paula Bowen accepted a check before more than 100-thousand enthusiastic fans.
Olympian Mark Spitz Joins Battle Against Kidney Cancer
Olympic swimming legend Mark Spitz, whose father has suffered from kidney cancer, Antigenics, and the Kidney Cancer Association have joined in spearheading a campaign promoting kidney cancer awareness and education. The nationwide educational outreach will focus on increasing awareness of kidney cancer and highlighting the need for new therapies.
Kidney Cancer Alliance on Capitol Hill
U.S. Senators Paul Sarbanes and Barbara Mikulski are urging increased federal funding for research in renal cancer as the result of effective lobbying by two kidney cancer advocates who belong to the Kidney Cancer Association (KCA).